Picture of MaxCyte logo

MXCT MaxCyte Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Annual cashflow statement for MaxCyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-19.1-23.6-37.9-41.1-44.6
Depreciation
Non-Cash Items8.699.37.559.8812
Unusual Items
Other Non-Cash Items
Changes in Working Capital-1.71-3.214.52-0.751-6.12
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities-10.7-14.8-21.7-27.6-34.4
Capital Expenditures-3.83-18.5-3.7-1.65-1.77
Purchase of Fixed Assets
Other Investing Cash Flow Items-191-6.3558.78.5827.7
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-195-24.8556.9325.9
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities2352.892.142.060.656
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash29-36.735.4-18.6-7.82